AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15659500
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC)
Trial: 11984212
Drug: Cholesterol-lowering therapy
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering therapy (CLT) using pravastatin 10-20 mg per day for 3 years
Trial: 11984212
Drug: Cholesterol-lowering therapy
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering therapy (CLT) using pravastatin
Trial: 9868971
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Metformin (2.55 g daily in three divided doses, n = 24)
Trial: 9868971
Drug: Moderate insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate insulin dose increase (20% of baseline, n = 23)
Trial: 15935019
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 400 mg
Trial: 15935019
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 800 mg
Trial: 7613532
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 100 mg
Trial: 822782
Drug: Carbol-fuchsin solution
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbol-fuchsin solution
Trial: 31729052
Drug: Nonablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative fractional laser therapy (FLT) followed by photodynamic therapy (PDT)
Trial: 31729052
Drug: Combined FLT-PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined FLT-PDT treatment
Trial: 21703382
Drug: Children's intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's intake of ice cream, chocolate, or french fries
Trial: 19139433
Drug: Bevacizumab (B)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (B) 10 mg/kg every 14 days and Erlotinib (E) 150 mg orally daily, continuously, for 28-day cycles
Trial: 17110262
Drug: Control force
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control force (0 g)
Trial: 11312068
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (20 g/d)
Trial: 9143867
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg every 6 h for 10 days
Trial: 9143867
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg every 12 h for 7 days
Trial: 9143867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of zileuton and terfenadine
Trial: 3129596
Drug: Preoperative nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative nutritional support (PNS) with 30 kcal/kg/day and 200 mg/kg/day of nitrogen for at least 7 days
Trial: 28376151
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection
Trial: 18472670
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment for rural adolescents
Trial: 18472670
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment for urban adolescents
Trial: 18472670
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment for both groups
Trial: 9020555
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with various tumors (lung cancers, lymphomas, and others)
Trial: 4044466
Drug: Vibunazole 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibunazole 400 mg tablets administered alone
Trial: 4044466
Drug: Vibunazole 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibunazole 400 mg tablets administered after 400 mg cimetidine
Trial: 4044466
Drug: Vibunazole 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibunazole 400 mg tablets administered after 30 ml diluted hydrochloric acid
Trial: 31687165
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) group intervention
Trial: 28962842
Drug: Etch-and-rinse (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etch-and-rinse (no preparation)
Trial: 28962842
Drug: Self-etch (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etch (no preparation)
Trial: 27253174
Drug: Ghrelin (0.5 μg kg(‐1) h(‐1))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (0.5 μg kg(‐1) h(‐1)) for 5 days
Trial: 20172327
Drug: Everolimus (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (target blood level, 3‐8 ng/mL)
Trial: 20172327
Drug: Azathioprine (2.0‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.0‐2.5 mg/kg/d)
Trial: 18308419
Drug: VNR 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VNR 30 mg/m² on day 1 and 8 plus CDDP 80 mg/m² on day 1 every 3 weeks
Trial: 11821466
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (RT) with five doses of 5 Gy
Trial: 9204057
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg twice a day
Trial: 9204057
Drug: Ranitidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 600 mg twice a day
Trial: 28422539
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (NIT) 140 mL daily for 3 days
Trial: 28531113
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus Policaptil Gel Retard® (PGR)
Trial: 21539743
Drug: CURB65-A risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CURB65-A risk class I (CURB65 score 0-1 and ProADM ≤0.75 nmol/l)
Trial: 21539743
Drug: CURB65-A risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CURB65-A risk class II (CURB65 score 2 and ProADM ≤1.5 nmol/l or CURB classes 0-1 and ProADM levels between 0.75-1.5 nmol/L)
Trial: 21539743
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment for CURB65-A risk class I
Trial: 14605970
Drug: Flexible multiple
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible multiple daily insulin (FMDI) regimen
Trial: 9364627
Drug: 50.4 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50.4 Gy schedule (2 x 1.8 Gy/day to a total dose of 50.4 Gy)
Trial: 9364627
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy schedule (2 x 2.5 Gy/day to a total dose of 30 Gy)
Trial: 9364627
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (1 daily fraction of 3 Gy up to 30 Gy)
Trial: 21129235
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (1.48 g EPA+DHA/d) for 12 weeks
Trial: 10992830
Drug: Patient-controlled i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled i.v. morphine alone (control)
Trial: 8787884
Drug: Valaciclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 500 mg (normotensive)
Trial: 8787884
Drug: Valaciclovir 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 1,000 mg (normotensive)
Trial: 8787884
Drug: Valaciclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 500 mg (hypertensive)
Trial: 3883493
Drug: Adriamycin administered
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin administered at 6 p.m. followed by cisplatin at 6 a.m.
Trial: 3883493
Drug: Adriamycin administered
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin administered at 6 a.m. followed by cisplatin at 6 p.m.
Trial: 27258524
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 1 μg/kg for 10 minutes, followed by continuous infusion at 0.5 μg/kg/h until 30 minutes before the end of surgery)
Trial: 11110739
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving treatment (n=128)
Trial: 28403084
Drug: Gabapentin alone
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin alone (group G)
Trial: 26254845
Drug: High-dose carotenoid-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Trial: 26254845
Drug: Low-dose carotenoid-rich
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Trial: 22364094
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl) irrigation with sequential irrigation of 3% H2O2, 5.2% NaOCl and 0.9% NaCl
Trial: 22364094
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly mentioned, but implied to be the other treatment group)
Trial: 19095827
Drug: 4% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% human albumin solution
Trial: 17005272
Drug: Simvastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20-40 mg/day) for 8 weeks
Trial: 12411457
Drug: Canrenone 50
RxNorm normalized name: canrenone
DrugBank: Canrenone (DB12221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenone 50 mg/d
Trial: 12411457
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and calcium antagonists (baseline treatment)
Trial: 9857348
Drug: (re)treatment during
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (re)treatment during long-term follow-up
Trial: 8580556
Drug: Continuous injection
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous injection of isosorbide dinitrate (ISDN) at 10 mg/h
Trial: 8580556
Drug: Intermittent injection
RxNorm normalized name: Jelco Intermittent Injection Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent injection of isosorbide dinitrate (ISDN) at 10 mg/10 min every 2 hours
Trial: 2213778
Drug: 80 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 micrograms triiodothyronine (T3) daily
Trial: 362282
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A therapy (vitamin A palmitate or 13‐cis vitamin A acid)
Trial: 23459487
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bedaquiline
Trial: 23459487
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg bedaquiline
Trial: 23459487
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg bedaquiline
Trial: 23459487
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg bedaquiline
Trial: 15001964
Drug: Oral sustained‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained‐release morphine, 1.9 mg/kg every 12 hours
Trial: 15001964
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of morphine at 0.04 mg/kg/hour
Trial: 15001964
Drug: Oral sustained‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained‐release morphine
Trial: 7918140
Drug: Quinapril (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (5-40 mg qd for MRI; 2.5-20 mg qd for CRF)
Trial: 2561750
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) administered at one 7500, 15000 or 30000 AXaU vial/day sc for 60 days
Trial: 2561750
Drug: Heparin calcium
RxNorm normalized name: HEPARIN CALCIUM
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin calcium administered at one or two 12500 IU vials/day sc for 60 days
Trial: 24651682
Drug: Lycopene intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene intervention (29.4 mg of lycopene per day via 11.5 oz of V8 100% vegetable juice for 30 days)
Trial: 20156067
Drug: Low-insulin step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-insulin step of the clamp in normal nonobese women
Trial: 20156067
Drug: High-insulin step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-insulin step in normal nonobese women
Trial: 12039991
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d sulodexide for 4 months
Trial: 12039991
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d sulodexide for 4 months
Trial: 12039991
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d sulodexide for 4 months
Trial: 12039991
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d sulodexide at T8
Trial: 2183405
Drug: Warfarin (prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (prothrombin time of 1.3‐1.8 times control)
Trial: 7058441
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with various therapeutic agents
Trial: 29101128
Drug: PSORI‐CM01 granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSORI‐CM01 granules (5.5 g, two times daily)
Trial: 29101128
Drug: Yinxieling tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinxieling tablets (five tablets, three times daily)
Trial: 25691622
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin at bedtime
Trial: 25691622
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin on awakening
Trial: 21088598
Drug: TCI sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI sufentanil (0.3 ng ml⁻¹)
Trial: 21088598
Drug: TCI remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI remifentanil (3 ng ml⁻¹)
Trial: 17192828
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (Actrapid)
Trial: 10813588
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (30 g)
Trial: 8665191
Drug: Single-dose ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin prophylaxis for hernia repair
Trial: 8665191
Drug: Single-dose ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin prophylaxis for ectopic pregnancy
Trial: 8665191
Drug: Single-dose ampicillin-metronidazole
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin-metronidazole prophylaxis for hysterectomy
Trial: 8665191
Drug: Single-dose ampicillin-metronidazole
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin-metronidazole prophylaxis for caesarean section
Trial: 8665191
Drug: Single-dose ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ampicillin prophylaxis with or without metronidazole
Trial: 8665191
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative penicillin therapy (control)
Trial: 6384863
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of daily 0.5 X 10(6) IE fibroblast interferon/kg body weight for 3-5 days
Trial: 25211285
Drug: CCaV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCaV at 120 CC per min
Trial: 25211285
Drug: CCaV at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCaV at 90 CC per min
Trial: 18824331
Drug: SAM-e (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM-e (800 mg)
Trial: 8387940
Drug: Men consuming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men consuming 10 g and 30 g of dietary fibre
Trial: 8387940
Drug: Women consuming
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women consuming 10 g and 30 g of dietary fibre
Trial: 3540223
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) verapamil (80 to 120 mg TID)
Trial: 3540223
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) verapamil (equivalent dose to IR)
Trial: 3330987
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) verapamil
Trial: 3330987
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) verapamil
Trial: 30109784
Drug: Calcium-Polystyrene Sulfonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-Polystyrene Sulfonate (Ca-PS) 3 × 5 g/day for 3 weeks
Trial: 12821234
Drug: Beraprost sodium
RxNorm normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beraprost sodium (median dose 120 microg four times a day)
Trial: 10813099
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms of ethinyl estradiol (EE) and 1 mg of norethindrone (NET) from days 6 through 10 (Group I)
Trial: 10813099
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms of ethinyl estradiol (EE) and 1 mg of norethindrone (NET) from days 8 through 12 (Group II)
Trial: 1649148
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of beta‐IFN through an Ommaya reservoir
Trial: 1649148
Drug: beta‐IFN followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐IFN followed by systemic chemotherapy (Cisplatin + Etoposide)
Trial: 6439234
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) administered as a dry powder via the spinhaler
Trial: 30412077
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 0.8 μg/kg, pumped for over 10 minutes)
Trial: 19658043
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day Zn as Zn sulfate
Trial: 9872200
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (ST)
Trial: 8551652
Drug: Arginine aspartate
RxNorm normalized name: Arginine aspartate
DrugBank: Arginine aspartate (DB15993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine aspartate (17 g free arginine)
Trial: 2164652
Drug: 50% trichloroacetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% trichloroacetic acid (single topical application)
Trial: 2164652
Drug: Saline (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo, single topical application)